trending Market Intelligence /marketintelligence/en/news-insights/trending/nzdhwkytx4enamm8xi4nmw2 content esgSubNav
In This List

ImmuPharma to sell Ureka unit, enters collaboration to develop cancer program

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


ImmuPharma to sell Ureka unit, enters collaboration to develop cancer program

ImmuPharma PLC plans to sell its unit Ureka, following a review by its board of directors.

The London-based drugmaker's board decided Ureka is not part of the company's ongoing strategy to use resources to develop late-stage assets.

Bordeaux, France-based Ureka is developing treatments for type 2 diabetes and nonalcoholic steatohepatitis, a buildup of fat in the liver. The therapies have shown success in preclinical studies, ImmuPharma said in a news release.

ImmuPharma will begin the process to sell the unit, but plans to retain an interest in Ureka's future commercial success.

Separately, ImmuPharma entered a collaboration to develop its Nucant cancer program with Incanthera Ltd, an oncology company.

Nucants are chemical structures which help inhibit nucleolin — an interaction that could potentially shrink tumors in cancer patients.

Under the deal, ImmuPharma invested £2 million to subscribe for 363,637 ordinary Incanthera shares, priced at £5.50 each. The purchase gave ImmuPharma a 16% shareholding in the company.

Incanthera will license and oversee development of ImmuPharma's Nucant cancer program. ImmuPharma granted Incanthera a period of exclusivity of until Dec. 31, during which the companies will agree on a license deal regarding Nucant technology.